$599

First Cagrisema Pivotal Trial on CT.gov; Lannett Doses 50% of Patients in Bs-glargine Pivotal Trial

Two cardiometabolic-related news items have been observed:  The first trial in the cagrisema pivotal program, called “REDEFINE,” has been observed (view CT.gov record); and Lannett provided updates to its bs-glargine pivotal trial (press release). Below, FENIX provides highlights and insights for the respective new items. 

This content is for Read Less members only.
Register
Already a member? Log in here